Replies to post #413 on Equity Field Notes from temporal sources

[DanWebzster]

SBBP seems like an undervalued biotech.

With 54.3M shares outstanding and a PPS of 2.85, the MC = 145M

Here are their products:

1) Korleva Ph3 read-out was positive. FDA approval could be expected by EOY 2021. Peak Sales are expected in the 300M/yr range.
If SBBP traded at a multiple of these sales, equity would be marked up substantially. What is being missed?

2) Keyveysis is being marketed, but will lose preferential pricing
on 8/7/22. Revs are ~30M/yr at present.

3) Veldoreotide is in Ph2 Acromegaly. If eventually approved, it would be one of six medications on the market for this condition.


SBBP will need to raise capital to take Korleva thru approval. I won't consider trading it until after a Cap Raise.